ClinicalTrials.Veeva
Menu

Find clinical trials for Triple Negative Breast Cancer in New Haven, CT

CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones

Related conditions:

Breast Cancer
Cancer
Carcinoma
Squamous Cell Carcinoma of Head and Neck
Endometrial Cancer
Non-Small-Cell Lung Carcinoma
Melanoma

Triple Negative Breast Cancer trials near New Haven, CT, USA:

Sacituzumab Govitecan +/- Pembrolizumab in Metastatic TNBC

This research study involves testing the safety and efficacy of an investigational intervention for patients with triple-negative b ...

Enrolling
Breast Cancer
Triple Negative Breast Cancer
Drug: Pembrolizumab
Drug: Sacituzumab Govitecan

Phase 2

Dana-Farber Cancer Institute
Dana-Farber Cancer Institute

Stamford, Connecticut, United States and 9 other locations

or paclitaxel (cohort 1) or with sacituzumab govitecan-hziy (cohort 2) in patients with non-surgically removable locally advanced or metastatic triple...

Active, not recruiting
Triple-Negative Breast Cancer
Drug: Sacituzumab Govitecan-hziy
Drug: Magrolimab

Phase 2

Gilead Sciences
Gilead Sciences

Stony Brook, New York, United States and 44 other locations

the feasibility of 1 year of adjuvant enzalutamide, an androgen receptor (AR) antagonist for the treatment of patients with early stage, AR(+) triple...

Active, not recruiting
Breast Cancer
Triple Negative Breast Cancer
Drug: Enzalutamide
Behavioral: assessment

Phase 2

Memorial Sloan Kettering Cancer Center (MSK)
Memorial Sloan Kettering Cancer Center (MSK)

Hartford, Connecticut, United States and 11 other locations

a study drug called Rucaparib, administered in combination with the type of radiation therapy that is usually given to women with your form of breast...

Active, not recruiting
Breast Cancer
Drug: Rucaparib
Radiation: Radiotherapy

Phase 1

Memorial Sloan Kettering Cancer Center (MSK)
Memorial Sloan Kettering Cancer Center (MSK)

Norwalk, Connecticut, United States and 7 other locations

maximum tolerated dose (MTD) of OTS167 administered via oral capsule (PO) to patients with relapsed/refractory locally advanced or metastatic breast...

Enrolling
Relapsed/Refractory Locally Advanced or Metastatic Breast Cancer and Triple Negative Breast Cancer
Drug: OTS167PO

Phase 1

OncoTherapy Science

Norwalk, Connecticut, United States and 3 other locations

This trial studies ladiratuzumab vedotin (LV) with pembrolizumab in patients with triple-negative breast cancer. -...

Active, not recruiting
Triple Negative Breast Neoplasms
Drug: Pembrolizumab
Drug: ladiratuzumab vedotin

Phase 1, Phase 2

Seagen
Seagen

Norwalk, Connecticut, United States and 49 other locations

This research study is studying a drug called Carboplatin with or without another study drug, Nivolumab as a possible treatment for triple-n ...

Active, not recruiting
Breast Cancer
Drug: Carboplatin
Drug: Nivolumab

Phase 2

Dana-Farber Cancer Institute
Dana-Farber Cancer Institute

Stamford, Connecticut, United States and 9 other locations

or pembrolizumab plus capecitabine in participants with triple negative breast cancer that still remains after su...

Enrolling
Triple Negative Breast Cancer
Drug: Capecitabine
Drug: Sacituzumab govitecan-hziy (SG)

Phase 3

Gilead Sciences
Gilead Sciences

Danbury, Connecticut, United States and 131 other locations

before the standard surgical procedure, to treat TNBC or HR+ HER2- breast cancers. The study drugs could shrink cancer, bu...

Enrolling
Breast Cancer
Drug: Pembrolizumab
Drug: Olaparib

Phase 2

Memorial Sloan Kettering Cancer Center (MSK)
Memorial Sloan Kettering Cancer Center (MSK)

Commack, New York, United States and 6 other locations

This study will assess the efficacy and safety of Niraparib in participants with either tumor mutation in the BRCA gene (tBRCAmut) HER2- breast...

Active, not recruiting
Neoplasms, Breast
Drug: Niraparib
Drug: Placebo

Phase 3

GlaxoSmithKline (GSK)
GlaxoSmithKline (GSK)

New Haven, Connecticut, United States and 226 other locations

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems